NextCure (NASDAQ:NXTC) is a biotechnology company focused on discovering and developing novel immunotherapies for cancer and other immune-related diseases. By leveraging its proprietary FIND-IO™ platform, NextCure aims to identify and advance therapeutic proteins and peptides that harness the body's immune system to fight disease effectively. The company's pipeline of projects includes several promising candidates in different stages of development, aimed at addressing unmet medical needs across various oncological indications. With a commitment to innovation and patient welfare, NextCure's objective is to push the boundaries of scientific research to provide new, effective treatments that improve patient outcomes and quality of life.